key: cord-0741643-lsa4u7lr authors: Asad Khan, Fatima Muhammad; Islam, Zarmina; Kazmi, Syeda Kanza; Hasan, Mohammad Mehedi; Yasmin, Farah; Costa, Ana Carla dos Santos; Ahmad, Shoaib; Essar, Mohammad Yasir title: The concomitant viral epidemics of Rift Valley fever and COVID-19: A lethal combination for Kenya date: 2022-01-03 journal: Trop Doct DOI: 10.1177/00494755211055247 sha: 692b94738dad9c5e2a7b107de7a046658c0b3577 doc_id: 741643 cord_uid: lsa4u7lr nan RVF owing to increasing livestock trade and migration, high density of livestock and vector populations, and a level terrain which is conducive to water-retaining soils. [1] [2] [3] Kenya faces several public health challenges, including understaffing, poor funding, and lack of specialized medical equipment and personnel to meet the needs of, with 65% of its population who reside in rural areas. 7 Furthermore, a recent analysis described a dire shortcoming in the Kenyan health infrastructure in terms of its hospital surge capacity. 8 Thus, with a concomitant viral epidemic of COVID-19, the Kenyan response to the current RVF outbreak is proving insufficient. As in several countries, the most significant deficiency is the absence of efficient vector control measures. 6 The first case of COVID-19 in Kenya was registered on March 12th, 2020. Since then, Kenya's overburdened, and understaffed medical facilities have been urgently drafted to tackle the pandemic. By September, 2021, Kenya registered over 200,000 confirmed cases and 4757 deaths, but had administered over 2.75 million vaccine doses but still only fully vaccinating 1.5% of the country's population. 9 Resources previously used to combat recurrent zoonosis outbreaks in the region, have been diverted towards COVID-19 management. Additionally, surveillance officers have transferred to monitoring COVID-19; the enormous demand for analysis of COVID-19 samples has hindered the processing of samples of other pathogens. This has thus led to widespread lack of resources to monitor, prevent, and treat RVF. 6 The risk of the current RVF outbreak transforming into an epidemic is further increased by the greater movement of people to rural areas in search of animal products such as meat and milk -since the government embargo in towns and commerce with abroad. 10 Presently, there are no definitive treatment available for RVF and even in severe cases, the management is supportive. However, live attenuated and inactivated vaccines against RVF are used in endemic regions. The immune response from inactivated vaccines is not strong and often requires repeat booster doses to maintain immunity, whereas a single dose of attenuated vaccine provides sufficient protection. 11, 12 No licensed vaccines are available for human use. Currently, WHO is collaborating with local bodies to determine the scope of the outbreak, its associated risk factors, vector surveillance and ecology mapping, details of which are being included in the weekly outbreak Situation Report. 13 Considerable preventative efforts have been established including animal quarantine, animal ante and post-mortem inspections and publicity. The use of safety equipment during slaughtering is an important consideration, but a rapid mass animal vaccination programme needs to be implemented. 6 Further concern is that RVF, as other viral diseases, such as dengue, measles, lassa fever, yellow fever, [14] [15] [16] [17] [18] and COVID-19, commences with fever, headache, and myalgia. However, differentiating features of RVF are photophobia, visual disturbance in 10% and retinal haemorrhage. Delayed paresis may occur, as may hepatic necrosis, jaundice, and haemorrhagic diatheses. 19 Whereas COVID-19 symptoms are generally respiratory, loss of taste or smell respective diagnosis requires PCR and ELISA (enzyme-linked immunosorbent assay) tests to distinguish between the two. 11 The author(s) received no financial support for the research, authorship, and/or publication of this article. The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Over 100 years of Rift Valley fever: a patchwork of data on pathogen spread and spillover Rift valley fever in Kenya: history of epizootics and identification of vulnerable districts Epidemiological investigation of a rift valley fever outbreak in humans and livestock in Kenya Rift valley fever: biology and epidemiology World Health Organization (WHO) World Health Organization (WHO) Devolution of healthcare system in Kenya: progress and challenges Assessing the hospital surge capacity of the Kenyan health system in the face of the COVID-19 pandemic Kenya: wHO coronavirus disease (COVID-19) dashboard With vaccination data World Health Organization (WHO) The next pandemic: rift valley fever? Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates Rift Valley fever -Kenya And COVID-19: a threefold challenge to public health security in Pakistan Dengue and coronavirus disease (COVID-19) syndemic: double threat to an overburdened healthcare system in Africa Lassa fever and COVID-19 in Africa: a double crisis on the fragile health system Measles returns to the democratic Republic of Congo: a new predicament amid the COVID-19 crisis The spread of yellow fever amidst the COVID-19 pandemic in Africa and the ongoing efforts to mitigate it Rift valley fever